Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MoonLake Immunotherapeutics (MLTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: MLTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $78.31
1 Year Target Price $78.31
| 12 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 66.84% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.10B USD | Price to earnings Ratio - | 1Y Target Price 78.31 |
Price to earnings Ratio - | 1Y Target Price 78.31 | ||
Volume (30-day avg) 16 | Beta 1.23 | 52 Weeks Range 31.42 - 58.26 | Updated Date 07/5/2025 |
52 Weeks Range 31.42 - 58.26 | Updated Date 07/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.85% | Return on Equity (TTM) -30.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2698722229 | Price to Sales(TTM) - |
Enterprise Value 2698722229 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -41.53 | Shares Outstanding 63474300 | Shares Floating 28324751 |
Shares Outstanding 63474300 | Shares Floating 28324751 | ||
Percent Insiders 15.34 | Percent Institutions 96.81 |
Upturn AI SWOT
MoonLake Immunotherapeutics
Company Overview
History and Background
MoonLake Immunotherapeutics was founded in 2020. It is a clinical-stage biotechnology company focused on developing novel therapies for immune-mediated diseases, particularly dermatology and rheumatology. Its initial focus is on nanobodies targeting the IL-17A/IL-17F heterodimer.
Core Business Areas
- Clinical Development: Focuses on advancing the clinical development of sonelokimab, its lead nanobody candidate, through various clinical trials targeting indications like hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis.
- Research and Development: Conducts research to identify and develop new therapeutic targets and nanobody-based therapies for immune-mediated diseases.
Leadership and Structure
The company is led by a management team with experience in biotechnology and pharmaceutical development. The organizational structure is focused on clinical development and research activities.
Top Products and Market Share
Key Offerings
- Sonelokimab: Sonelokimab is MoonLake's lead product candidate, a nanobody targeting IL-17A/IL-17F. Currently in clinical trials for hidradenitis suppurativa (HS), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Competitors in the IL-17 inhibitor market include Novartis (Cosentyx), Eli Lilly (Taltz) and UCB (Bimekizumab).
Market Dynamics
Industry Overview
The industry is characterized by increasing demand for novel therapies targeting immune-mediated diseases, driven by a growing understanding of the underlying disease mechanisms and a need for more effective treatment options.
Positioning
MoonLake is positioned as a company focused on developing nanobody-based therapies for immune-mediated diseases, differentiating itself through its novel approach and potential for improved efficacy and safety.
Total Addressable Market (TAM)
The TAM for IL-17 inhibitors in indications like hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis is estimated to be significant, potentially reaching billions of dollars annually. MoonLake is aiming to capture a portion of this market with sonelokimab.
Upturn SWOT Analysis
Strengths
- Novel nanobody platform
- Targeting IL-17A/IL-17F heterodimer
- Strong clinical trial results (initial)
- Experienced management team
- Focus on high unmet need indications
Weaknesses
- Single product focus (sonelokimab)
- Clinical trial risks
- Dependence on financing
- Limited commercial infrastructure
- Competition from established players
Opportunities
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial data
- Market growth in immune-mediated diseases
- Regulatory approvals
Threats
- Clinical trial failures
- Competition from existing and emerging therapies
- Regulatory hurdles
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- NVS
- LLY
- UCB
Competitive Landscape
MoonLake faces competition from established pharmaceutical companies with approved IL-17 inhibitors. Its competitive advantage lies in its nanobody technology and potential for improved efficacy and safety. However, it needs to successfully navigate the clinical and regulatory hurdles to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth is characterized by the advancement of sonelokimab through clinical trials and raising capital to fund these activities.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of sonelokimab.
Recent Initiatives: Recent initiatives include initiation and continuation of clinical trials for sonelokimab in various indications, and expansion of the scientific team.
Summary
MoonLake Immunotherapeutics is a promising clinical-stage biotech company developing nanobody-based therapies. Its focus on IL-17A/IL-17F inhibition and strong initial clinical data are strengths. Key risks include clinical trial failures and competition. Future success hinges on achieving positive clinical trial results and securing regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MoonLake Immunotherapeutics
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-10-20 | Co-Founder, CEO & Director Dr. Jorge Santos da Silva Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 100 | Website https://www.moonlaketx.com |
Full time employees 100 | Website https://www.moonlaketx.com | ||
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.